NSF Pitches 5-Year Funding For Centers

WASHINGTON—NSF Director Erich Bloch has thrown Congress a curveball in the hope that legislators won’t knock his request for a 19 percent budget increase out of the ballpark. Bloch's 1989 budget contains a new pitch to salvage his plan for a dozen or more university-based science and technology centers. It requests $150 million up front—nearly half of the overall $333 million increase sought by NSF—for a five-year program that would be isolated from the foundationR

Written byJeffrey Mervis
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WASHINGTON—NSF Director Erich Bloch has thrown Congress a curveball in the hope that legislators won’t knock his request for a 19 percent budget increase out of the ballpark.

Bloch's 1989 budget contains a new pitch to salvage his plan for a dozen or more university-based science and technology centers. It requests $150 million up front—nearly half of the overall $333 million increase sought by NSF—for a five-year program that would be isolated from the foundation’s regular accounts that support individual and group research.

NSF officials hope that this novel funding approach will protect their proposed budget from the fate of last year’s request, which Congress shrunk so far below expectations (see THE SCIENTIST, January 11, p. 3) that Bloch was forced to cancel a more modest, $30 million S&T centers program. They admit the idea is also a subtle effort to force Congress to set long-range priorities for science.

The ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies